Whether confirmed in humans, the combined use of CXCR2/PD-1 inhibitors might represent a successful strategy to improve NASH-related HCC therapy by restoring cancer immunosurveillance. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.